For research use only. Not for use in humans.

Vilobelimab (Anti-Complement C5)

Synonyms: CaCP-29, IFX-1 Cat.No.A3101 Purity:99%

Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD.

Quality Control

Batch: A310101 Purity: 99% Protein concentration: 5.5mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Mechanism of Action

Description	Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/34806021/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2250440-41-4
Isotype	Human IgG4SP
Source	CHO
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.